Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash Flows From Operating Activities:
Net loss	$ (1,192,031)	$ (1,121,918)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and Amortization	15,629	12,448
Changes in assets and liabilities:
Prepaid expenses and other receivables	69,121	93,889
Accounts payable and other liabilities	(20,584)	77,904
Prepayment to related party for clinical trials		249,459
Net cash used in operating activities	(1,127,865)	(688,218)
Cash Flows from Investing Activities:
Purchase of property and equipment	(6,641)	(5,606)
Purchase of intangible assets	(57,630)	(50,334)
Net Cash used in investing activities	(64,271)	(55,940)
Cash Flows From Financing Activities:
Advances from related party	423,237	239,717
Net proceeds from issuance of common stock		10,000,000
Net cash provided by financing activities	423,237	10,239,717
Net increase (decrease) in cash	(768,899)	9,495,559
Effect of exchange rate changes on cash	(1,041,712)	988
Cash at beginning of period	9,403,965	354,759
Cash at end of period	$ 7,593,354	$ 9,851,306